Mark A Behlke
Overview
Explore the profile of Mark A Behlke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
6700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goraczniak R, Wall B, Behlke M, Lennox K, Ho E, Zaphiros N, et al.
Mol Ther Nucleic Acids
. 2025 Jan;
36(1):102403.
PMID: 39817191
[This corrects the article DOI: 10.1038/mtna.2013.24.].
2.
Cromer M, Majeti K, Rettig G, Murugan K, Kurgan G, Bode N, et al.
Mol Ther
. 2023 Feb;
31(4):1074-1087.
PMID: 36793210
While a number of methods exist to investigate CRISPR off-target (OT) editing, few have been compared head-to-head in primary cells after clinically relevant editing processes. Therefore, we compared in silico...
3.
Magis W, DeWitt M, Wyman S, Vu J, Heo S, Shao S, et al.
iScience
. 2022 May;
25(6):104374.
PMID: 35633935
Background: A point mutation in sickle cell disease (SCD) alters one amino acid in the β-globin subunit of hemoglobin, with resultant anemia and multiorgan damage that typically shortens lifespan by...
4.
Aoki Y, Rocha C, Lehto T, Miyatake S, Johansson H, Hashimoto Y, et al.
Front Physiol
. 2021 Nov;
12:689179.
PMID: 34721051
Splice-switching antisense oligonucleotide- (SSO-) mediated correction of framedisrupting mutation-containing premessenger RNA (mRNA) transcripts using exon skipping is a highly promising treatment method for muscular diseases such as Duchenne muscular dystrophy...
5.
Fananas-Baquero S, Quintana-Bustamante O, Dever D, Alberquilla O, Sanchez-Dominguez R, Camarena J, et al.
Mol Ther Methods Clin Dev
. 2021 Sep;
22:237-248.
PMID: 34485608
Pyruvate kinase deficiency (PKD), an autosomal-recessive disorder, is the main cause of chronic non-spherocytic hemolytic anemia. PKD is caused by mutations in the pyruvate kinase, liver and red blood cell...
6.
Zhang L, Zuris J, Viswanathan R, Edelstein J, Turk R, Thommandru B, et al.
Nat Commun
. 2021 Jul;
12(1):4500.
PMID: 34282150
No abstract available.
7.
Zhang L, Zuris J, Viswanathan R, Edelstein J, Turk R, Thommandru B, et al.
Nat Commun
. 2021 Jun;
12(1):3908.
PMID: 34162850
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. Here we isolate an engineered variant, "AsCas12a Ultra",...
8.
Valentin R, Wong C, Alharbi A, Pradeloux S, Morros M, Lennox K, et al.
Nucleic Acids Res
. 2021 May;
49(11):6082-6099.
PMID: 34057477
Oligonucleotide-based therapeutics have the capacity to engage with nucleic acid immune sensors to activate or block their response, but a detailed understanding of these immunomodulatory effects is currently lacking. We...
9.
Kurgan G, Turk R, Li H, Roberts N, Rettig G, Jacobi A, et al.
Mol Ther Methods Clin Dev
. 2021 May;
21:478-491.
PMID: 33981780
CRISPR systems enable targeted genome editing in a wide variety of organisms by introducing single- or double-strand DNA breaks, which are repaired using endogenous molecular pathways. Characterization of on- and...
10.
Cromer M, Camarena J, Martin R, Lesch B, Vakulskas C, Bode N, et al.
Nat Med
. 2021 Mar;
27(4):677-687.
PMID: 33737751
β-Thalassemia pathology is due not only to loss of β-globin (HBB), but also to erythrotoxic accumulation and aggregation of the β-globin-binding partner, α-globin (HBA1/2). Here we describe a Cas9/AAV6-mediated genome...